OncoMed to Present at Two Upcoming Investor Conferences in September
August 29 2018 - 4:00PM
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage
biopharmaceutical company focused on discovering and developing
novel anti-cancer therapeutics, today announced that John Lewicki,
Ph.D., President and Chief Executive Officer of OncoMed, will
provide a corporate update at two upcoming investor conferences.
- Wells Fargo Securities 2018 Healthcare Conference in Boston, MA
on September 5, 2018 at 9:40 am Eastern Time
- 20th Annual Rodman & Renshaw Global Investment Conference,
sponsored by H.C. Wainwright & Co., LLC in New York, NY on
September 6, 2018 at 4:40 pm Eastern Time
To access the live webcasts and subsequent archived recordings
of these and other company presentations, please visit OncoMed's
website at www.oncomed.com/invest/events.cfm. A replay of each
presentation will be available for 30 days following the date of
the event.
About OncoMed Pharmaceuticals OncoMed
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on discovering and developing novel anti-cancer
therapeutics. OncoMed has internally discovered a broad pipeline of
investigational drugs intended to address the fundamental biology
driving cancer's growth, resistance, recurrence and metastasis.
Navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), anti-TIGIT
(etigilimab), and rosmantuzumab (anti-RSPO3, OMP-131R10) are part
of OncoMed's strategic alliance with Celgene Corporation. OncoMed
is independently developing GITRL-Fc (OMP-336B11), as well as
continuing to pursue new drug discovery research. For further
information about OncoMed Pharmaceuticals, please see
www.oncomed.com.
Contacts Sylvia Wheeler
sylvia.wheeler@oncomed.com |
Alexandra Santos
asantos@wheelhouselsa.com |
ONCOMED PHARMACEUTICALS INC (NASDAQ:OMED)
Historical Stock Chart
From Aug 2024 to Sep 2024
ONCOMED PHARMACEUTICALS INC (NASDAQ:OMED)
Historical Stock Chart
From Sep 2023 to Sep 2024